The stock of Gamida Cell Ltd (NASDAQ:GMDA) last traded at $0.33, up 10.56% from the previous session.
Data from the available sources indicates that Gamida Cell Ltd (NASDAQ:GMDA) is covered by 4 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $4.00. Given the previous closing price of $0.30, this indicates a potential upside of 1233.33 percent. GMDA stock price is now -57.62% away from the 50-day moving average and -74.87% away from the 200-day moving average. The market capitalization of the company currently stands at $44.42M.
In total, 0 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target of $11, Alliance Global Partners recently initiated with Buy rating for Gamida Cell Ltd (NASDAQ: GMDA).
A total of 9.60% of the company’s stock is owned by insiders.
With an opening price of $0.3048 on Friday morning, Gamida Cell Ltd (NASDAQ: GMDA) set off the trading day. During the past 12 months, Gamida Cell Ltd has had a low of $0.22 and a high of $2.51. As of last week, the company has a debt-to-equity ratio of 224.26, a current ratio of 3.32, and a quick ratio of 3.20. The fifty day moving average price for GMDA is $0.7748 and a two-hundred day moving average price translates $1.3268 for the stock.
The latest earnings results from Gamida Cell Ltd (NASDAQ: GMDA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.17 by 0.16. This compares to -$0.29 EPS in the same period last year. The net profit margin was -11434.03% and return on equity was -1103.79% for GMDA. For the current quarter, analysts expect GMDA to generate $1.06M in revenue.
Gamida Cell Ltd(GMDA) Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company’s lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
